Precision Medication Therapy Strategy In Crohn’s Disease: Financial Advantages

Precision Medication Therapy Strategy In Crohn's Disease: Financial Advantages Overview In this study, the cost-effectiveness of precision-guided dosing (PGD) of infliximab (IFX) for patients with Crohn's disease (CD) who lose response to biologics was evaluated in comparison to two other dose intensification strategies (DIS).   A hybrid model combining Markov and decision tree elements

Metronidazole For Vulval Crohn’s Disease Treatment

Metronidazole For Vulval Crohn's Disease Treatment Overview Cutaneous vulval Crohn's disease (VCD), an often overlooked extra-intestinal manifestation of Crohn's disease (CD), poses diagnostic and therapeutic challenges due to its potential for significant edema, painful fissures, and lasting disfigurement of the vulval anatomy. The lack of consensus on optimal management adds to the

Precision Medication Therapy Strategy In Crohn’s Disease: Financial Advantages